Feature Story
Cancer researchers: It’s time to pay more attention to ‘miracle’ patients
FRIDAY, August 26, 2016 (The Washington Post) — Call it luck — or a medical miracle. During clinical trials for experimental cancer drugs, some patients simply respond better than others. And a tiny fraction of patients see dramatic results, responding so well to treatment that they survive forms of cancers that quickly kill their counterparts. Stories about people like Emily Whitehead, the then-6-year-old who was enrolled in a clinical trial that saved her life, make headlines. But statistically speaking, they’re insignificant, mere outliers. Because they deviate so far from the norm, these “exceptional responders” are often overlooked by researchers.
You might have also missed…
The Developing World Needs a Cancer Moonshot
Aug 31, Forbes
Patients, Fearing Pricey Follow-Ups, May Shy Away From Some Colon Cancer Tests
Aug 30, Kaiser Health News
HPV, Hepatitis B vaccinations can prevent many cancers
Aug 30, The Tennessean
ESPN’s Chris Mortensen says he’s beaten back cancer enough to work again
Aug 31, The Washington Post
